Quotables
"The idea that cavalry will be replaced by these iron coaches is absurd. It is little short of treasonous."
Aide-de-camp to Field Marshal Haig ; At a tank demonstration, 1916
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7666829 | Compositions for elastogenesis and connective tissue treatment The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and ... | 02/23/2010 |
| 7662767 | Polynucleotide intercalator interceptors and inhibitors A method of using modified xanthine molecules as a binding agent is disclosed. Xanthine molecules with at least one substitution of a methyl group at the N1, N3, N7, or N9 position bind to intercalating molecules efficiently. This method can be applied to inhibiting... | 02/16/2010 |
| 7645732 | Treating hepatitis C virus infection Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HVC release from the cell. The methods can be used to decrease serum viremia of a... | 01/12/2010 |
| 7589057 | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems Biocompatible microparticles include an ophthalmically active alpha-2 adrenergic receptor agonist and a biodegradable polymer. The microparticles include oil-in-water emulsified microparticles which can be used to treat an ocular condition, such as glaucoma. ... | 09/15/2009 |
| 7589056 | Agent for the prevention and treatment of sexually transmitted diseases-I Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases. ... | 09/15/2009 |
| 7569536 | Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting prot... | 08/04/2009 |
| 7547673 | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially direc... | 06/16/2009 |
| 7531499 | Medicinal composition The present invention provides a medicinal composition comprising (1) a pharmacologically active substance, (2) a drug absorbefacient and (3) a taurine compound or a polyamine. A taurine compound has an effect of suppressing or preventing damage of the intestinal mu... | 05/12/2009 |
| 7531500 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 05/12/2009 |
| 7521414 | Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140 A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in sediments off La Jolla, Calif... | 04/21/2009 |
| 7507704 | Receptor modulated cancer protocols The present invention discloses that prior art protocols that administer HER receptor blockers concurrently with phase specific cytotoxic chemotherapeutics result in antagonistic function that prevents subsequent administrations of phase specific cytotoxic from func... | 03/24/2009 |
| 7507703 | Method of cancer screening; method of cancer treatment; and method of diabetes treatment A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering a needle biopsy; if the result is positive administering a PET scan;... | 03/24/2009 |
| 7449442 | EGFR inhibitors promote axon regeneration Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron. | 11/11/2008 |
| 7423008 | Derivatives of mithramycin and methods of making and uses thereof The invention, in one aspect, generally relates to mithramycin derivatives from mutated Streptomyces argillaceus and their production. The invention also relates using the derivatives for the treatment of various diseases. Finally, the invention relates to a ... | 09/09/2008 |
| 7419683 | Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier which contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a... | 09/02/2008 |
| 7419964 | Treatment of HSV-related pathologies using ssDNA A composition for treatment of HSV-related pathologies including an expression vector for altering expression of a target sequence in an HSV-infected cell by production of single-stranded cDNA (ssDNA) in the cell in vivo suspended for topical application to an affec... | 09/02/2008 |
| 7411042 | Tumor associated nucleic acids and uses therefor The invention describes SAGE (sdph3.10) and sdp3.5 tumor associated nucleic acids, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acid molecules, and antibodies relating ... | 08/12/2008 |
| 7405205 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribo... | 07/29/2008 |
| 7402725 | WIP, a WASP-associated protein Described herein is a novel gene and its product, WIP, which associates with WASP. The subject invention relates to the isolated WIP gene or cDNA and transgenic mammals that have the WIP gene disrupted in their genome. Also the subject of this invention are methods ... | 07/22/2008 |
| 7390497 | Poly(ester amide) filler blends for modulation of coating properties Provided herein is a PEA polymer blend and coatings or implantable devices formed therefrom. The PEA polymer blend is formed of a PEA polymer and a material capable of hydrogen bonding with the PEA. The PEA polymer blend can form a coating on an implantable device, ... | 06/24/2008 |
| 7390780 | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are assoc... | 06/24/2008 |
| 7390890 | Inhibitors of nucleoside metabolism The present invention provides compounds having the formula: wherein A is CH or N; B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H, halogen or SCH3; R is an opt... | 06/24/2008 |
| 7384558 | Compositions capable of inhibiting reactive oxygen and carbonyl species Therapeutic compositions are provided. The compositions include a single molecule that can display both antioxidant and carbonyl trapping properties. This can effectively reduce inflammation, oxidative stress and carbonyl stress, such as to prevent and/or treat card... | 06/10/2008 |
| 7384907 | Method of treating infection with ABl tyrosine kinase inhibitors The present invention relates to a method of preventing or treating a pathogen infection comprising administering to a mammal in need thereof an effective amount of an inhibitor of Abl tyrosine kinase. ... | 06/10/2008 |
| 7378488 | Somatostatin antagonists The present invention is directed to a somatostatin antagonist according to formula (I), wherein A1 is an optionally substituted aromatic ∝-amino acid; A2 is an optionally substituted aromatic ∝-amino acid; A3 is Dab, Dap, Lys or... | 05/27/2008 |
| 7375073 | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective ... | 05/20/2008 |
| 7371524 | Substituted azaporphyrins as fluorescence labels The present invention relates to marker components, fluorescent probes, oligonucleotides, hybridization assays, and immunoassays using such products, and methods for making such products. According to the present invention, detectably labeled marker components are p... | 05/13/2008 |
| 7365049 | Afamin-containing compositions and methods of use The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress. ... | 04/29/2008 |
| 7365073 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, a... | 04/29/2008 |
| 7361517 | Real time method of detecting acute inflammatory conditions This invention relates to the diagnosis and/or monitoring of patients with inflammatory diseases or conditions, including systemic lupus erythematosus, particularly for diagnosis of the acute stage of the disease, including methods and kits for carrying out this act... | 04/22/2008 |
| 7358223 | Biodegradable cationic polymers Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells. ... | 04/15/2008 |
| 7358222 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 04/15/2008 |
| 7357928 | Method for the diagnosis and prognosis of malignant diseases Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. ... | 04/15/2008 |
| 7354894 | Preventing airway mucus production by administration of EGF-R antagonists Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks th... | 04/08/2008 |
| 7355056 | Transfection agents The present invention provides compounds, compositions and methods that enhance the transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents... | 04/08/2008 |
| 7351421 | Drug-eluting stent having collagen drug carrier chemically treated with genipin A method for treating vulnerable plaques of a patient, comprising: providing a biodegradable stent comprising a first supporting zone made of a first biodegradable material, wherein the supporting zone comprises at least a portion of continuous circumference of the ... | 04/01/2008 |
| 7345018 | Method of treating side effects induced by therapeutic agents The invention relates to agents for the prevention of organ damage, in particular of the kidneys and the inner ear, induced by the administration of aminoglycosides. Agents according to the invention are all substances which are megalin and/or cubilin antagonists (i... | 03/18/2008 |
| 7341988 | Method of treating influenza with geranyl-geranyl acetone To provide a novel preventive and/or therapeutic agent against a virus, disclosed is a preventive and/or therapeutic agent against a viral infection containing geranyl-geranyl acetone as an active ingredient. Also, disclosed are inducers for increasing the activity ... | 03/11/2008 |
| 7342048 | Bioabsorbable pharmaceutical formulation A bioabsorbable release-sustaining pharmaceutical formulation using a biodegradable release-sustaining base material which can prevent an effective component drug from being released too rapidly just after administration of the formulation and then allow continued r... | 03/11/2008 |
| 7338953 | Method of treating chronic fatigue syndrome Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. ... | 03/04/2008 |